Novartis CMO John Tsai, MD, said that while the drug didn’t show the benefit the company was hoping for, it helped to improve scientific understanding of COVID-19 and the role of similar drugs.
“There’s still an urgent need for effective ways to combat COVID-19, and we will continue to apply our best scientific minds in support of the global pandemic response,” Dr. Tsai said.
Novartis said it will submit the full results to a peer-reviewed journal soon.
The trial results don’t affect any other trials for Ilaris, including those testing it for non-small cell lung cancer.
Read the full news release here.
More articles on pharmacy:
CVS CEO to step down, hand reins to Aetna chief
Allogene reports patient death tied to its CAR-T drug
Sandoz, Civica Rx ship first drug to US hospitals